Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
2017
We have previously described the safety and efficacy of
pegylated interferon-α2a therapy in a cohort of 62 patients with
myeloproliferative neoplasm-associated
myelofibrosisfollowed in centers affiliated to the French Intergroup of
Myeloproliferative neoplasms. In this study, we report their long-term outcomes and correlations with mutational patterns of driver and non-driver mutations analyzed by targeted next generation sequencing. The median age at diagnosis was 66 years old, the median follow-up since starting
pegylated interferonwas 58 months. At the time of analysis, 30 (48.4%) patients were alive including 16 still being treated with
pegylated interferon. The median survival of patients with intermediate and high-risk prognostic Lille and dynamic
International Prognostic Scoring Systemscores treated with
pegylated interferonwas increased in comparison to that of historical cohorts. In addition, overall survival was significantly correlated with the duration of
pegylated interferontherapy (70 versus 30 months after 2 years of treatment, P −12 ). JAK2 V617F allele burden was decreased by more than 50% in 58.8% of patients and two patients even achieved complete molecular response. Next-generation sequencing analyses performed in 49 patients showed that 28 (57.1%) of them carried non-driver mutations. The presence of at least one additional mutation was associated with a reduction of both overall and leukemia-free survival. These findings in a large series of patients with
myelofibrosissuggest that
pegylated interferontherapy may provide a survival benefit for patients with intermediate- or high-risk Lille and dynamic
International Prognostic Scoring Systemscores. It also reduced the JAK2 V617F allele burden in most patients. These results further support the use of
pegylated interferonin selected patients with
myelofibrosis.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
34
References
33
Citations
NaN
KQI